Welcome to our dedicated page for Emmaus Life Scie SEC filings (Ticker: EMMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Emmaus Life Sciences, Inc. (EMMA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Emmaus is a commercial-stage biopharmaceutical company focused on Endari®, its prescription-grade L-glutamine oral powder for sickle cell disease, and its filings give detailed insight into financial performance, capital structure, and key agreements.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports, which Emmaus references in its press releases when discussing risks and uncertainties, including doubt about its ability to continue as a going concern. These reports typically include information on net revenues from Endari sales, operating expenses, income or loss from operations, other income or expense, liquidity, and stockholders’ deficit.
Emmaus also files multiple Form 8-K current reports to disclose material events. Recent 8-Ks describe an Exchange Agreement involving the issuance of common stock and a convertible promissory note in exchange for an outstanding convertible note, the resignation of a director, and the entry into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. Under that license, Emmaus granted NeoImmuneTech exclusive rights to market, sell, and distribute Endari and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada, subject to specified conditions. The 8-Ks summarize terms such as upfront payments, royalties, conversion prices, and adjustment mechanisms for notes.
On Stock Titan, AI-powered tools can help interpret these EMMA filings by highlighting the sections that explain new licensing arrangements, changes in debt obligations, and references to going concern risks. Users can quickly locate information on Emmaus’ material definitive agreements, unregistered sales of securities, and other corporate actions without reading every page of the underlying documents. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, and 10-Ks for Emmaus Life Sciences are reflected promptly, while Form 4 and other ownership-related filings can be used to track insider and major holder activity where available.
Emmaus Life Sciences filed its Q3 2025 10-Q, highlighting a sharp revenue decline and liquidity strain alongside a going concern warning. Q3 revenue was $3.38 million versus $5.48 million a year ago, and the company posted a net loss of $2.08 million versus net income of $1.83 million in Q3 2024. Operating profit of $0.70 million was outweighed by other expense of $2.19 million, driven mainly by interest expense of $1.93 million.
For the nine months, revenue was $8.60 million versus $13.36 million. Cash was $0.29 million with current liabilities of $64.17 million, and total liabilities of $80.24 million against assets of $20.76 million, resulting in a stockholders’ deficit of $59.49 million. Management states there is substantial doubt about continuing as a going concern without restructuring debt and raising additional financing. The company also recorded a $0.53 million realized loss year‑to‑date on its Telcon convertible bond.